Annual EBIT
$25.40 M
+$69.21 M+157.99%
December 31, 2023
Summary
- As of February 8, 2025, SPRO annual earnings before interest & taxes is $25.40 million, with the most recent change of +$69.21 million (+157.99%) on December 31, 2023.
- During the last 3 years, SPRO annual EBIT has risen by +$103.68 million (+132.45%).
- SPRO annual EBIT is now at all-time high.
Performance
SPRO EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$18.59 M
+$468.00 K+2.46%
September 30, 2024
Summary
- As of February 8, 2025, SPRO quarterly earnings before interest & taxes is -$18.59 million, with the most recent change of +$468.00 thousand (+2.46%) on September 30, 2024.
- Over the past year, SPRO quarterly EBIT has dropped by -$67.74 million (-137.83%).
- SPRO quarterly EBIT is now -137.83% below its all-time high of $49.15 million, reached on December 31, 2023.
Performance
SPRO Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$2.49 M
-$21.96 M-112.77%
September 30, 2024
Summary
- As of February 8, 2025, SPRO TTM earnings before interest & taxes is -$2.49 million, with the most recent change of -$21.96 million (-112.77%) on September 30, 2024.
- Over the past year, SPRO TTM EBIT has dropped by -$27.89 million (-109.79%).
- SPRO TTM EBIT is now -109.70% below its all-time high of $25.65 million, reached on March 31, 2024.
Performance
SPRO TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
SPRO EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +158.0% | -137.8% | -109.8% |
| 3 y3 years | +132.4% | -137.8% | -109.8% |
| 5 y5 years | +159.3% | -137.8% | -109.8% |
SPRO EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +128.9% | -137.8% | +38.7% | -109.7% | +97.7% |
| 5 y | 5-year | at high | +128.9% | -137.8% | +38.7% | -109.7% | +97.7% |
| alltime | all time | at high | +128.9% | -137.8% | +38.7% | -109.7% | +97.7% |
Spero Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$18.59 M(-2.5%) | -$2.49 M(-112.8%) |
| Jun 2024 | - | -$19.06 M(+36.3%) | $19.48 M(-24.1%) |
| Mar 2024 | - | -$13.98 M(-128.4%) | $25.65 M(+1.0%) |
| Dec 2023 | $25.40 M(-158.0%) | $49.15 M(+1357.6%) | $25.40 M(+739.5%) |
| Sep 2023 | - | $3.37 M(-126.2%) | $3.03 M(-125.2%) |
| Jun 2023 | - | -$12.89 M(-9.4%) | -$12.02 M(-56.6%) |
| Mar 2023 | - | -$14.23 M(-153.1%) | -$27.70 M(-36.8%) |
| Dec 2022 | -$43.81 M(-50.1%) | $26.77 M(-329.3%) | -$43.81 M(-55.2%) |
| Sep 2022 | - | -$11.68 M(-59.1%) | -$97.88 M(-10.0%) |
| Jun 2022 | - | -$28.57 M(-5.9%) | -$108.73 M(+10.1%) |
| Mar 2022 | - | -$30.34 M(+11.1%) | -$98.73 M(+12.4%) |
| Dec 2021 | -$87.82 M(+12.2%) | -$27.30 M(+21.2%) | -$87.82 M(+11.9%) |
| Sep 2021 | - | -$22.52 M(+21.3%) | -$78.48 M(+4.7%) |
| Jun 2021 | - | -$18.57 M(-4.4%) | -$74.98 M(+0.1%) |
| Mar 2021 | - | -$19.42 M(+8.1%) | -$74.88 M(-4.3%) |
| Dec 2020 | -$78.28 M | -$17.96 M(-5.6%) | -$78.28 M(-9.2%) |
| Sep 2020 | - | -$19.02 M(+2.9%) | -$86.20 M(+1.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2020 | - | -$18.48 M(-19.0%) | -$85.17 M(+6.0%) |
| Mar 2020 | - | -$22.82 M(-11.8%) | -$80.34 M(+27.1%) |
| Dec 2019 | -$63.22 M(+47.7%) | -$25.88 M(+43.9%) | -$63.22 M(+30.6%) |
| Sep 2019 | - | -$17.98 M(+31.7%) | -$48.42 M(+17.0%) |
| Jun 2019 | - | -$13.65 M(+139.7%) | -$41.37 M(+9.8%) |
| Mar 2019 | - | -$5.70 M(-48.6%) | -$37.69 M(-12.0%) |
| Dec 2018 | -$42.81 M(+2.6%) | -$11.08 M(+1.4%) | -$42.81 M(-6.4%) |
| Sep 2018 | - | -$10.94 M(+9.7%) | -$45.72 M(+2.2%) |
| Jun 2018 | - | -$9.97 M(-7.8%) | -$44.75 M(-0.4%) |
| Mar 2018 | - | -$10.82 M(-22.7%) | -$44.95 M(+10.9%) |
| Dec 2017 | -$41.73 M(+25.6%) | -$14.00 M(+40.5%) | -$40.53 M(+14.7%) |
| Sep 2017 | - | -$9.97 M(-2.0%) | -$35.34 M(+6.2%) |
| Jun 2017 | - | -$10.16 M(+58.8%) | -$33.29 M(+44.0%) |
| Mar 2017 | - | -$6.40 M(-27.4%) | -$23.12 M(+38.3%) |
| Dec 2016 | -$33.22 M(+149.3%) | -$8.81 M(+11.3%) | -$16.72 M(+111.3%) |
| Sep 2016 | - | -$7.91 M | -$7.91 M |
| Dec 2015 | -$13.33 M | - | - |
FAQ
- What is Spero Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Spero Therapeutics?
- What is Spero Therapeutics annual EBIT year-on-year change?
- What is Spero Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Spero Therapeutics?
- What is Spero Therapeutics quarterly EBIT year-on-year change?
- What is Spero Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Spero Therapeutics?
- What is Spero Therapeutics TTM EBIT year-on-year change?
What is Spero Therapeutics annual earnings before interest & taxes?
The current annual EBIT of SPRO is $25.40 M
What is the all time high annual EBIT for Spero Therapeutics?
Spero Therapeutics all-time high annual earnings before interest & taxes is $25.40 M
What is Spero Therapeutics annual EBIT year-on-year change?
Over the past year, SPRO annual earnings before interest & taxes has changed by +$69.21 M (+157.99%)
What is Spero Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of SPRO is -$18.59 M
What is the all time high quarterly EBIT for Spero Therapeutics?
Spero Therapeutics all-time high quarterly earnings before interest & taxes is $49.15 M
What is Spero Therapeutics quarterly EBIT year-on-year change?
Over the past year, SPRO quarterly earnings before interest & taxes has changed by -$67.74 M (-137.83%)
What is Spero Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of SPRO is -$2.49 M
What is the all time high TTM EBIT for Spero Therapeutics?
Spero Therapeutics all-time high TTM earnings before interest & taxes is $25.65 M
What is Spero Therapeutics TTM EBIT year-on-year change?
Over the past year, SPRO TTM earnings before interest & taxes has changed by -$27.89 M (-109.79%)